The main components of COVID-19 management are homeostasis management and the initiation of respiratory support. The role of antiviral medications in the treatment of COVID-19 is unclear. As a result, patients should be isolated with supportive care, and vital signs should be monitored (
3).
The most common clinical symptoms of COVID-19 cases are acute hypoxemic respiratory failure (AHRF) caused by bilateral pulmonary infiltrates, which leads to ARDS requiring invasive ventilator support (
18). Happy hypoxemia (also referred to as silent hypoxemia), the clinical manifestation in which the patient is awake, calm, and responsive with severe hypoxemia with no evidence of dyspnea and with almost normal lung compliance, is caused by COVID-19; however, the patient’s condition could deteriorate rapidly and without warning. The main step to reverse the hypoxemia is increasing FiO
2, which can be done by providing O
2 through utilizing a simple nasal prong or facemask (up to 5 - 6 L/minute and up to 10 - 15 L/minute in case of prolonged period of desaturation) (
19). Applying prone position can improve ventilation to posterior zones of lung, which leads to improved ventilation-perfusion mismatch (
6). High flow rates with nasal oxygen, in turn, result in increased FiO
2. For opening the collapsed airways and alveoli, tight-fitting full-face mask, continuous positive airway pressure (CPAP), or helmet can be used to apply continuous positive airway pressure. Therefore, the decision to intubate should be based not only on hypoxemia but also on respiratory distress and fatigue (
19).
Intubation and invasive ventilation support are needed in approximately 3.2 percent of COVID-19 cases. These methods are more important than high-flow oxygen treatment and bilevel positive airway pressure (PAP) ventilation in cases of AHRF (both acute and chronic) to increase transpulmonary pressure, open collapsed alveoli, refine oxygenation, reduce oxygen debt, and provide a better opportunity for lung healing (
20). Moreover, avoiding the use of advanced respiratory support, in particular noninvasive ventilation and high flow oxygen, can decrease the spread of droplets and infection of clinicians. Radovanovic et al. stated that using a CPAP through a helmet is an effective way for the recruitment of diseased alveolar units and improvement of hypoxemia (
18).
For patients with normal airway, the corrected rapid sequence induction using mask ventilation prior to intubation, combined with video-laryngoscopy, has provided rapid tracheal intubation and has been universally successful. A tracheal intubation technique based on rapid sequence induction provided the following benefits in COVID-19 patients: (1) reducing the risk of pulmonary aspiration of stomach contents; (2) facilitating rapid intubation for improving oxygenation and ventilation for making hypoxemia better; and (3) minimizing the time of exposure to patients leading to a reduction in whole exposure to coronavirus (
4,
21).
In some recent studies, flexible fiberoptic bronchoscopy was studied in both awake and under general anesthesia patients with COVID-19. The results showed that, compared to mask preoxygenation, less hypoxemia is observed while using high-flow nasal cannula oxygen (HFNO) through flexible fiberoptic bronchoscopic intubation under general anesthesia (
21). Moreover, HFNO offers a more rapid intubation length and limited risk of desaturation in tries at fiberoptic tracheal intubation than preoxygenation using facemask ventilation in critically ill patients with COVID-19 pneumonia. HFNO is potentially advantageous in rapid sequence induction and intubation of severe COVID-19 cases. Although HFNO is recommended during intubation for preventing exacerbation of hypoxemia, generally, the use of HFNO is not recommended since it may generate droplets and aerosol (
4,
12). Fiberoptic bronchoscopy decreases tracheal intubation-related coughing leading to the spread of the virus. Nonetheless, using neuromuscular blocking agents reduces coughing and increases the probability of intubation success with laryngoscopy (
4,
22,
23).
The most appropriate timing for intubation in severe cases is not well-known and might depend on the condition of patients (
19). However, according to recent studies, tracheal intubation should be performed in the early stages of illness, whenever possible, to avoid performing the procedure in the presence of severe hypoxemia, which may aid in lowering total mortality in COVID-19 patients. According to Yao et al., tracheal intubation in the early stages of COVID-19 helps to reduce the risk of cardiovascular collapse (during anesthesia and intubation) and lower the risk of pneumothorax. Additionally, large-volume ventilation and the use of hypoxemia-correcting maneuvers immediately after tracheal intubation should be avoided (
4,
21).
In patients with maxillofacial trauma, ventilation with a mask and endotracheal intubation may be difficult, in which instability of the cervical spine and airway bleeding could aggravate the condition. Bilateral mandibular fractures can significantly obstruct the airway, preventing fiberoptic bronchoscopy or direct laryngoscopy from being performed. As a result, tracheostomy under local anesthesia is a relatively safe and feasible method. For minimizing the spread of virus, the following preventive strategies should be given consideration: (1) an appropriate depth of anesthesia (prevent coughing); (2) not performing positive pressure and stopping mechanical ventilation immediately before entering the endotracheal tube; (3) reducing the use of suctions during the procedure; and (4) preferring cuffed non-fenestrated tracheostomy tubes (
24).
Rahimzadeh et al. discovered a novel finding in terms of intubation length: patients with higher respiratory rates on admission required a longer period of intubation. The respiratory rate and the score of chest CT involvement can be considered as a prognostic factor for estimating the length of intubation and establishing the severity of the illness (
2).